You are here

Validating establishment of functional safety in skin interfacewith deeply porous transcutaneous pylon for direct skeletal attachment of limb prostheses

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R44AR079960-01
Agency Tracking Number: R44AR079960
Amount: $1,708,048.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: NIAMS
Solicitation Number: PA20-260
Timeline
Solicitation Year: 2020
Award Year: 2021
Award Start Date (Proposal Award Date): 2021-09-24
Award End Date (Contract End Date): 2023-08-30
Small Business Information
26 MALLARD DR
Sharon, MA 02067-1518
United States
DUNS: 803723790
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 MARK PITKIN
 (781) 784-4434
 mpitkin@tuftsmedicalcenter.org
Business Contact
 MARK PITKIN
Phone: (781) 784-4434
Email: mpitkin@tuftsmedicalcenter.org
Research Institution
N/A
Abstract

Research efforts of the Poly-Orth International demonstrated feasibility of the novel
“Residuum-Integration Prosthetic Technology" to be used in direct skeletal attachment of
limb prosthetics. The technology includes a “Skin and Bone Integrated Pylon” (SBIP),
which connects the residuum with external limb prosthesis and can be especially
beneficial for patients who can not use traditional socket attachment of the prostheses.As histopathology analysis after the study with small and large animals has
demonstrated, the SBIP is integrated not only with the residual bone, but also with the
residuum’s skin minimizing the risk of infection and secondary trauma. The investigators
developed an optimal porous titanium matrix and design of the Skin and Bone Integrated
Pylon to maximize the ingrowth of bone and skin cells of the residuum to the SBIP
without compromising strength of the implanted device. The technological study on the
process of manufacturing of the composite porous structure enforced with a permeable
internal frame. Parameters of the SBIP’s specification are protected by the US Patent
#8257435.During the proposed translational pre-clinical study, the animal trials will be
conducted according to the FDA requirements to ensure smooth translation to the trials
in humans. It will include large animals (pigs) and the implantation period up to 22
months.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government